The ongoing investigation into the possible link between Byetta and pancreatic cancer took a step forward in June when FDA officials met with the National Institutes of Health to discuss the safety of the popular type 2 diabetes medication and similar drugs like Januvia, reports.

At the meeting held June 12th, the U.S. Food and Drug Administration said it may set up a study that delves deeper into whether the type 2 diabetes drugs, also known as incretin mimetics, can lead to Byetta pancreatic cancer and other life-threatening illnesses, according to a article published the same day. An FDA spokeswoman said one option may be for either drug companies or the agency to conduct a large clinical trial to show adverse event patterns.

In order to accurately investigate the situation involving type 2 diabetes drugs, the chief scientific and medical officer of the American Diabetes Association went on record saying, “We need some calm heads and to look at the data and try and make some reasonable judgments out of this. We are all anxious to be sure the therapies we have available are safe, but we also want to make sure we have therapies available.”

The June meeting was held amidst rising concerns over the potential for Byetta, Januvia and other incretin mimetics to cause the following pancreatic side effects:

  • Pancreatitis
  • Pancreatic cancer
  • Thyroid cancer

Concerns Grow Over Byetta Pancreatitis Link

In February, a study published in JAMA Internal Medicine showed that patients hospitalized for pancreatitis were twice as likely to be taking Byetta or Januvia in comparison to diabetics who did not have pancreatitis.

Two years earlier, research from Gastroenterology in February 2011 showed a six-fold increase of pancreatitis cases in Byetta or Januvia users; a 2.9-fold increase in pancreatic cancer in patients who took Byetta, and a 2.7-fold increase of pancreatic cancer in Januvia users.

Prior to this study, the U.S. Food and Drug Administration (FDA) issued  a public health alert about the potential health risks associated with Byetta in 2008 after receiving a high number of Byetta pancreatitis reports, which included two deaths.

Given the complaint reports from diabetics alleging Byetta pancreatic cancer and other injuries, there is likely to be a large litigation over this drug, as well as other incretin mimetics in the future. While a federal proceeding has not been created for Byetta lawsuit filings, court records show that a motion to consolidate claims has been filed with the U.S. Judicial Panel on Multidistrict Litigation.

File a Byetta Pancreatic Cancer Lawsuit

If you took Byetta for the treatment of type 2 diabetes and were diagnosed with pancreatitis, pancreatic cancer or thyroid cancer, don’t hesitate in calling a lawyer who can help you file a claim. Contact Bernstein Liebhard LLP at (877) 779-1414.

Published July 12, 2013 by